Selective inhibition of DNA methyltransferase enzymes as a novel strategy for cancer treatment

Current Opinion in Molecular Therapeutics

Volumn 4, Issue 2, 2002, Pages 130-137

  Reid, Gregory K ^a   Besterman, Jeffrey M ^a   MacLeod, A Robert ^a  

^a METHYLGENE INC   (Canada)

Author keywords

Antisense inhibitor; CpG island; DNA methyltransferase; Tumor suppressor genes

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; AZACITIDINE; CADHERIN; CGP 69846A; CYTOSINE DERIVATIVE; CYTOTOXIC AGENT; DNA METHYLTRANSFERASE; ENZYME INHIBITOR; HEMOGLOBIN F; ISIS 3521; MESSENGER RNA; MG 118; MG 88; MG 98; NUCLEOSIDE ANALOG; OBLIMERSEN; ONCOPROTEIN; PHOSPHOROTHIOIC ACID DERIVATIVE; PROTEIN BCL 2; PROTEIN FOS; PROTEIN KINASE C ALPHA; PROTEIN P15; PROTEIN P16; REGULATOR PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; UVOMORULIN; VIMENTIN;

5' UNTRANSLATED REGION; ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CARCINOGENESIS; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CPG ISLAND; DIARRHEA; DOSE RESPONSE; DRUG CLASSIFICATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME INHIBITION; ENZYME SPECIFICITY; FEVER; GENE ACTIVATION; GENE EXPRESSION; GENE FUNCTION; GENE LOSS; GENE SILENCING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; METHYLATION; MOUSE; MYELODYSPLASTIC SYNDROME; NAUSEA AND VOMITING; NONHUMAN; PHASE 2 CLINICAL TRIAL; TUMOR SUPPRESSOR GENE; CHEMISTRY; DRUG ANTAGONISM; ENZYMOLOGY; GENE DELETION; GENETICS; METABOLISM; NEOPLASM; REVIEW;

CLINICAL TRIALS; DNA MODIFICATION METHYLASES; ENZYME INHIBITORS; GENES, TUMOR SUPPRESSOR; HUMAN; NEOPLASMS; SEQUENCE DELETION; SUBSTRATE SPECIFICITY; HUMANS;

ANIMALIA; STAPHYLOCOCCUS PHAGE 3A;

EID: 0035997960     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. DNA methylation affects the formation of active chromatin
2. Role for DNA methylation in genomic imprinting
3. Dynamic methylation adjustment and counting as part of imprinting mechanisms
4. Regulation of mouse satellite DNA replication time
5. Gene methylation patterns and expression
6. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer
7. Mouse DNA methylase: Methylation of native DNA
8. DNA (cytosine-5)-methyltransferases in mouse cells and tissues. Studies with a mechanism-based probe
9. Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases
10. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality
11. DNA methyltransferases DNMT3A and DNMT3B are essential for de novo methylation and mammalian development
12. Suppression of intestinal neoplasia by DNA hypomethylation
13. The human DNA methyltransferase (DNMTs) 1, 3a and 3b: Coordinate mRNA expression in normal tissues and overexpression in tumors
14. The DNMT3B DNA methyltransferase gene is mutated in the ICF immunodeficiency syndrome
15. Expression of antisense to DNA methyltransferase mRNA induces DNA demethylation and inhibits tumorigenesis
16. Regulation of DNA methylation by the Ras signaling
17. Role of DNA 5-methylcytosine transferase in cell transformation by fos
18. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor
19. Toxicity of 5-aza-2′-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation
20. Germline p16 mutations in familial melanoma
21. Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing
22. Down-regulation of human DNA-(cytosine-5) methyltransferase induces cell cycle regulators p16(ink4A) and p21(WAF/Cip1) by distinct mechanisms
23. Changes in DNA methylation in neoplasia: Pathophysiology and therapeutic implications
24. Phase I/II trial of ISIS 3521, an antisense inhibitor of PKCα, with carboplatin and paclitaxel in non-small cell lung cancer
25. Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 Given as a 21-day continuous infusion every 4 weeks
26. Phase I study of the DNA methyltransferase 1 inhibitor MG98 as a twice weekly two hour intravenous infusion
27. INK4B gene in hematopoietic progenitors and peripheral blood cells in myelodysplastic syndromes
28. INK4b gene methylation and myelodysplastic syndromes
29. 5-Aza-2′-deoxycytidine (Decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: Past, present and future trends